<DOC>
	<DOC>NCT00871494</DOC>
	<brief_summary>Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and eradication rate in the western clinical trials. Development of azithromycin intravenous formulation would bring the clinical benefit to patients with pelvic inflammatory disease (PID) in Japan.</brief_summary>
	<brief_title>Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<criteria>Both of following symptoms should be observed. Lower abdominal pain and/or lower abdominal tenderness. Hypochondrial pain and/or hypochondrial tenderness (tenderness of uterus or adnexa of uterus). Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides. Hepatic dysfunction (AST, ALT, total bilirubin &gt; 3 times institutional normal).</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>